Biotechnology Breast Cancer cancer Cancer Discovery Cancer screening Clinical Trials genes

New Study Finds Nanoparticles Show Promise in Therapy for Triple-Negative Breast Cancer

Approximately 10-20 percent of diagnosed breast cancers are found to be triple-negative, meaning the breast cancer cells test negative for estrogen and progesterone receptors as well as HER2 receptors, genes that can play a role in the development of breast cancer. Triple-negative breast cancer can be more aggressive and difficult to treat as the cancer cells do not respond to hormonal therapies or therapies that target HER2 receptors. A new